Author:
Easton Victoria,McPhillie Martin,Garcia-Dorival Isabel,Barr John N.,Edwards Thomas A.,Foster Richard,Fishwick Colin,Harris Mark
Reference26 articles.
1. Balmith, M., & Soliman, M. E. (2017). Potential Ebola drug targets–filling the gap: A critical step forward towards the design and discovery of potential drugs. Biologia, 72(1), 1-13.
2. Balmith, M., Faya, M., & Soliman, M. E. (2017). Ebola virus: A gap in drug design and discovery‐experimental and computational perspective. Chemical Biology & Drug Design, 89(3), 297-308.
3. Bandyopadhyay, B., Verma, N., & Chouhan, U. (2016). In Sillico analysis of newly identified potential drug lead compound against VP40 for the treatment of Ebola virus infection. International Journal of Advanced Biotechnology and Research, 7(4), 1357-1365.
4. Basu, A., Mills, D. M., Mitchell, D., Ndungo, E., Williams, J. D., Herbert, A. S., Dye, J. M., Moir, D. T., Chandran, K., Patterson, J. L., et al. (2015). Novel small molecule entry inhibitors of Ebola virus. The Journal of Infectious Diseases, 212(suppl_2), S425-S434.
5. Broni, E., Ashley, C., Adams, J., Manu, H., Aikins, E., Okom, M., Miller III, W. A., Wilson, M. D., & Kwofie, S. K. (2023). Cheminformatics-based study identifies potential Ebola VP40 inhibitors. International Journal of Molecular Sciences, 24(7), 6298. doi:10.3390/ijms24076298